Corticotrophin‐releasing hormone and corticotrophin‐ releasing hormone binding protein in normal and pre‐eclamptic human pregnancies
Author(s)
PERKINS, AV
LINTON, EA
EBEN, F
SIMPSON, J
WOLFE, CDA
REDMAN, CWG
Griffith University Author(s)
Year published
1995
Metadata
Show full item recordAbstract
Objective: To measure the plasma levels of corticotrophin‐releasing hormone and corticotrophin‐releasing hormone binding protein in normal pregnancy and in pregnancies complicated by pre‐eclampsia.
Setting: John Radcliffe Hospital, Oxford and St Thomas's Hospital, London.
Subjects: One hundred and twenty pregnant women sampled prospectively throughout gestation, of whom 91 experienced a normal pregnancy and eight developed pre‐eclampsia; in a second study, 10 women with severe pre‐eclampsia, presenting at a range of gestational ages, were sampled once and compared with appropriately matched normal pregnant women.
Main ...
View more >Objective: To measure the plasma levels of corticotrophin‐releasing hormone and corticotrophin‐releasing hormone binding protein in normal pregnancy and in pregnancies complicated by pre‐eclampsia. Setting: John Radcliffe Hospital, Oxford and St Thomas's Hospital, London. Subjects: One hundred and twenty pregnant women sampled prospectively throughout gestation, of whom 91 experienced a normal pregnancy and eight developed pre‐eclampsia; in a second study, 10 women with severe pre‐eclampsia, presenting at a range of gestational ages, were sampled once and compared with appropriately matched normal pregnant women. Main outcome measure: Plasma levels of corticotrophin‐releasing hormone determined by immunoradiometric assay. Plasma levels of corticotrophin‐releasing hormone binding protein measured by direct radioimmunoassay. Results: In the prospective study, plasma samples from women with pre‐eclampsia exhibited higher (390.2 versus 292.7 pmol/l at 36 weeks) levels of corticotrophin‐releasing hormone and significantly lower (5.24 versus 8.14 nmol/l at 36 weeks, P 0.002) levels of corticotrophin‐releasing hormone binding protein than normal controls. In the second, single time point study a significant elevation in CRH (P < 0.002) and reduction in CRH‐BP (P < 0.001) was found in pre‐eclamptic pregnancies compared with controls. Conclusions: In human pregnancies complicated by pre‐eclampsia there is an elevated level of corticotrophin releasing hormone whilst there is less corticotrophin‐releasing hormone binding protein; therefore there is a net increase in free potentially bioactive hormone which may play a role in the pathology of the disease.
View less >
View more >Objective: To measure the plasma levels of corticotrophin‐releasing hormone and corticotrophin‐releasing hormone binding protein in normal pregnancy and in pregnancies complicated by pre‐eclampsia. Setting: John Radcliffe Hospital, Oxford and St Thomas's Hospital, London. Subjects: One hundred and twenty pregnant women sampled prospectively throughout gestation, of whom 91 experienced a normal pregnancy and eight developed pre‐eclampsia; in a second study, 10 women with severe pre‐eclampsia, presenting at a range of gestational ages, were sampled once and compared with appropriately matched normal pregnant women. Main outcome measure: Plasma levels of corticotrophin‐releasing hormone determined by immunoradiometric assay. Plasma levels of corticotrophin‐releasing hormone binding protein measured by direct radioimmunoassay. Results: In the prospective study, plasma samples from women with pre‐eclampsia exhibited higher (390.2 versus 292.7 pmol/l at 36 weeks) levels of corticotrophin‐releasing hormone and significantly lower (5.24 versus 8.14 nmol/l at 36 weeks, P 0.002) levels of corticotrophin‐releasing hormone binding protein than normal controls. In the second, single time point study a significant elevation in CRH (P < 0.002) and reduction in CRH‐BP (P < 0.001) was found in pre‐eclamptic pregnancies compared with controls. Conclusions: In human pregnancies complicated by pre‐eclampsia there is an elevated level of corticotrophin releasing hormone whilst there is less corticotrophin‐releasing hormone binding protein; therefore there is a net increase in free potentially bioactive hormone which may play a role in the pathology of the disease.
View less >
Journal Title
BJOG: an International Journal of Obstetrics and Gynaecology
Volume
102
Issue
2
Subject
Technology